Literature DB >> 15312508

[Expression and significance of Toll-like receptor 4 of splenic macrophage in patients with hypersplenism due to portal hypertension].

Zong-Fang Li1, Yu Zhang, Jun Gao, Pan-Jian Zhang, Ji-Xin Wang, Xiao-Gong Liu.   

Abstract

OBJECTIVE: To observe the change in expression of Toll-like receptor 4 (TLR4) of splenic macrophage in patients with hypersplenism due to portal hypertension (PH), and investigate the role of TLR4 of splenic macrophage in hypersplenism.
METHODS: Splenectomy was performed on 20 patients with hypersplenism due to PH (hypersplenism group) and 6 patients with rupture of spleen by trauma (control group) and the specimens of spleen were collected. The splenic macrophages were isolated by adhibit wall method. The expression of TLR4 of splenic macrophage was detected by immunohistochemical method (SABC), and the result was analyzed by the image analysis system. The phagocytosis of splenic macrophage was measured by chicken red blood cell (CRBC) phagocytosis assay. The level of serum endotoxin was detected before the operation by limulus assay. The results of these 2 groups were compared, and correlation analysis was made among different results of the hypersplenism group.
RESULTS: The expression of TLR4 of splenic macrophage was 109 +/- 32 in the hypersplenism group, significantly higher than that of the control group (62 +/- 5, P < 0.01). The rate of phagocytosis and index of phagocytosis of splenic macrophage in the hypersplenism group were 12.6% +/- 3.0% and 0.146 +/- 0.035 respectively, both significantly higher than those of the control group (6.9% +/- 0.5% and 0.076 +/- 0.008 respectively, both P < 0.01) The level of endotoxin of the hypersplenism group was 0.28 EU/ml +/- 0.21 EU/ml, significantly higher than that of the control group (0.054 EU/ml +/- 0.014 EU/ml, P < 0.05). The rate of phagocytosis and the index of phagocytosis of splenic macrophage were notably positively correlated with the expression of TLR4 (r = 0.601, P < 0.01 and r = 0.553, P < 0.05), and the level of endotoxin (r = 0.724 P < 0.01 and r = 0.506, P < 0.05). The expression of TLR4 of splenic macrophage was positively correlated with the level of endotoxin (r = 0.525, P < 0.05).
CONCLUSION: The expression of TLR4 of splenic macrophage in patients with hypersplenism due to PH was increased significantly. It may be one of the important factors of hypersplenism due to PH that "endotoxemia-->increase of expression of TLR4 of splenic macrophage (activation of TLR of splenic macrophage)-->increased destruction of red blood cells by macrophage".

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15312508

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  6 in total

1.  Changes in count and function of splenic lymphocytes from patients with portal hypertension.

Authors:  Zong-Fang Li; Shu Zhang; Gao-Bo Lv; Ying Huang; Wei Zhang; Song Ren; Jun Yang; Shuang-Suo Dang
Journal:  World J Gastroenterol       Date:  2008-04-21       Impact factor: 5.742

2.  Development of splenic surgery in China.

Authors:  Hongchi Jiang; Xianqi Zhao; Yue Gao
Journal:  Front Med China       Date:  2007-02-01

3.  Difference in gene expression of macrophage between normal spleen and portal hypertensive spleen identified by cDNA microarray.

Authors:  Feng Yan; Xiao-Min Wang
Journal:  World J Gastroenterol       Date:  2007-06-28       Impact factor: 5.742

Review 4.  The spleen in liver cirrhosis: revisiting an old enemy with novel targets.

Authors:  Liang Li; Mubing Duan; Weisan Chen; An Jiang; Xiaoming Li; Jun Yang; Zongfang Li
Journal:  J Transl Med       Date:  2017-05-23       Impact factor: 5.531

5.  Hypersplenism: History and current status.

Authors:  Yunfu Lv; Wan Yee Lau; Yejuan Li; Jie Deng; Xiaoyu Han; Xiaoguang Gong; Ning Liu; Hongfei Wu
Journal:  Exp Ther Med       Date:  2016-09-07       Impact factor: 2.447

Review 6.  Portal hypertension as immune mediate disease.

Authors:  Sara Manti; Lucia Marseglia; Gabriella D'Angelo; Martina Filippelli; Caterina Cuppari; Eloisa Gitto; Claudio Romano; Teresa Arrigo; Carmelo Salpietro
Journal:  Hepat Mon       Date:  2014-06-07       Impact factor: 0.660

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.